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Objective: Numerous reports have confirmed the early benefits of lung volume
reduction surgery for selected patients with emphysema. This report documents the
long-term survival and functional results after lung volume reduction surgery.
Methods: Between January 1993 and June 2000, a total of 250 consecutive patients
underwent bilateral lung volume reduction surgery through median sternotomy at our
institution. All patients had disabling dyspnea, thoracic hyperinflation, and a heteroge-
neous pattern of emphysema with suitable target areas for resection. Preoperative
pulmonary rehabilitation was required and post-rehabilitation data were used as the
baseline for data analysis. Follow-up ranged from 1.8 to 9.1 years (median 4.4 years).
Results: Prolonged air leaks (7 days) were the most common complication
(45.2%, n  113). Reexploration rates for air leak and bleeding were 3.2% (n  8)
and 1.2% (n  3), respectively. Eighteen patients (7.2%) required reintubation and
mechanical ventilation. The in-hospital mortality in this series was 4.8% (n  12).
The median length of hospitalization was 9 days (range 4-168 days). Kaplan-Meier
survivals after lung volume reduction surgery were 93.6%, 84.4%, and 67.7% at 1,
3, and 5 years, respectively. Eighteen patients (7.2%) have subsequently undergone
lung transplantation after a median interval of 4.3 years (range 2.1-6.4 years).
Spirometric values, lung volumes, and gas exchange parameters improved after
surgery. The forced expiratory volume in 1 second and the residual volume showed
statistically significant improvements between preoperative values and each time
point of follow-up. Health-related quality of life showed significant postoperative
improvement and with time correlated well with the improvement in forced expi-
ratory volume in 1 second.
Conclusions: Lung volume reduction surgery produces significant functional im-
provement for selected patients with emphysema. For most of these patients,
benefits appear to last at least 5 years.
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Chronic obstructive pulmonary disease is thefourth leading cause of death in the UnitedStates and a leading cause of disability. Avariety of treatments, such as smoking ces-sation, bronchodilators, corticosteroids,and exercise rehabilitation, can improve
quality of life for patients with emphysema.1,2 Numerous
surgical procedures have been proposed to treat emphy-
sema, but only resection of giant bullae and lung transplan-
tation have provided sustained benefit. Four decades ago,
Brantigan and colleagues3 suggested that partial pulmonary
resection could produce symptomatic and functional im-
provement in some patients with emphysema. This proce-
dure resulted in high mortality and modest clinical benefit
and did not gain wide acceptance. Lung volume reduction
surgery (LVRS) was reintroduced by our center in 1993.4
Although several large series have reported low operative
mortality and significant improvement in the short and
intermediate terms,5-8 controversy remains regarding the
long-term benefits of this procedure.
Medicare suspended payment for LVRS in 1996 and
cosponsored, along with the National Institutes of Health, a
long-term randomized trial comparing LVRS with ongoing
medical management. The primary outcome was the effect
of LVRS on survival relative to control survival. Secondary
outcomes included exercise tolerance, quality of life, and
measured lung function. Four randomized clinical trials
comparing LVRS with ongoing medical management have
been published or reported to date.9-12 Three of these four
have demonstrated benefits of LVRS and have confirmed
the progressive decline of the control group, consistent with
the known natural history of emphysema. The fourth study,
a preliminary report from the National Emphysema Treat-
ment Trial Research (NETT) Group, identified certain high-
risk groups within the study that had a high mortality and
little benefit.12 To date there have been limited published
data regarding long-term functional outcome.13-16 The pur-
pose of this report is to describe the long-term survival and
functional results of the first 250 consecutive bilateral
LVRS procedures performed at our institution.
Methods
Patient Population
From the outset of our program, a prospective database was
maintained for all patients. Data included results of pulmonary
function studies, exercise testing, and quality of life assessment.
These were obtained at 6 months, at 1 year, and at subsequent
yearly intervals whenever possible. A review was conducted from
records of the 250 consecutive patients who underwent bilateral
LVRS at Barnes Jewish Hospital between January 1993 and June
2000. During this period 50 unilateral LVRS procedures and 35
bullectomies were performed, but these procedures are not in-
cluded in this report. For the 250 patients studied, the mean
follow-up was 4.8 years, with a minimum interval of 18 months.
Follow-up was complete for all patients but 1. Many patients live
a long distance from Missouri, and we could not require them to
return at fixed intervals. The follow-up data were therefore based
on routine appointments and thus could be collected several
months before or after the desired follow-up time point.
Details of the selection process have been reported previous-
ly.17,18 Critical selection criteria are marked hyperinflation of the
chest and sufficient regional variation in the emphysema to provide
target areas of useless lung accessible to surgical resection. The
degree of regional parenchymal destruction is analyzed by stan-
dardized computed tomography of the chest, and the regional
distribution of function is assessed by radionuclide ventilation-
perfusion lung scanning. Thoracic distention is evaluated by chest
radiography, and lung volumes are determined by plethysmogra-
phy. Although the selection process remains subjective in many
ways, attempts have been made to identify objective patterns in
selection.19 Inclusion and exclusion criteria are summarized in
Table 1.
The on-site evaluation includes physical examination, pulmo-
nary function tests, arterial blood gas analysis (at rest with room
air), a 6-minute walk test, and questionnaires assessing quality of
life and dyspnea. Fifty percent of more than 800 patients with
on-site evaluations were excluded from surgery, and 17% were
deferred. The most common reason for exclusion was lack of
target areas for surgical resection (76%).
Patients judged suitable for surgery were enrolled in a preop-
erative pulmonary rehabilitation program, usually for 3 months
(median 97 days). Medical therapy was optimized, and dietary
regimens were prescribed to adjust body weight to within 20% of
the calculated ideal value.
Patients were reassessed the week before surgery with an
interval history and physical examination, chest radiography, com-
plete pulmonary function tests, arterial blood gas measurement,
6-minute walk test, and quality-of-life questionnaires. The postre-
habilitation, preoperative data were used as the baseline for com-
parisons with postoperative data.
Pulmonary function tests were performed with a Medgraphics
System 1085 (Medical Graphics Corporation, St Paul, Minn) be-
fore and after administration of aerosolized albuterol, and the best
values for forced vital capacity and forced expiratory volume in 1
second (FEV1) were chosen for the data analysis. Lung volumes
were determined by plethysmography, and diffusion capacity for
carbon monoxide (DLCO) was measured by the single-breath tech-
nique. During the 6-minute walk test, supplemental oxygen was
administered by nasal cannula as needed to maintain the arterial
oxygen saturation at 90% or better.
Quality of life was assessed with two self-administered ques-
tionnaires, the Nottingham Health Profile20 and the Medical Out-
comes Study 36-Item Short-Form Health Survey.21 To measure
postoperative patient satisfaction, patients were asked to assess
their own satisfaction with the operation according to how they felt
at the time. There were five possible responses: poor, fair, good,
very good, and excellent. All tests were performed during periods
of clinical stability.
A complete battery of pulmonary function testing was per-
formed at our institution during the postoperative follow-up peri-
ods; an abbreviated battery of tests (FEV1 and residual volume
[RV]) from other institutions was also used. Follow-up evaluation
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also included arterial blood gas measurement on room air,
6-minute walk test, and completion of questionnaires assessing
dyspnea and quality of life.
Surgical Technique
All procedures were performed through a median sternotomy,
except one that was done through a bilateral muscle-sparing tho-
racotomy because of a previous sternotomy for coronary bypass
surgery. The operative technique has evolved little since our initial
experience. Initially, successive applications of the stapler pro-
duced an inverted U-shaped line of excision, from the medial
aspect of the right upper lobe towards the apex and down the
posterolateral aspect. Now the line of excision from the horizontal
fissure is carried straight toward the posterolateral aspect of the
right upper lobe, almost completely removing the entire lobe. The
same procedure is then repeated on the left, where the upper
portion of the upper lobe is excised, leaving only the lingula in
place. The transition has been gradual and subtle; therefore there is
no ability to distinguish patients retrospectively with regard to the
style of stapler application. In 19 patients with lobar destruction
and complete fissures, an anatomic lobectomy was performed
rather than wedge excisions. When a residual space remained at
the apex of the chest at the end of the procedure, we often created
a pleural tent to allow the apical pleura to drop down to the upper
surface of the remaining lung. Two chest tubes were placed on
either side. The pleura was closed bilaterally before closure of the
sternotomy. The chest tubes were brought out through the upper
abdomen in a subxiphoid position.
All patients were extubated in the operating room or shortly
thereafter in the postanesthesia recovery area. One patient required
immediate reintubation and spent the night with ventilatory sup-
port, with successful extubation the next morning. The surgical
and anesthetic techniques have been previously described else-
where.4,5,22
Postoperative Management
Our standard postoperative management has been previously de-
scribed elsewhere.5 Adequate postoperative pain relief was facil-
itated by the use of continuous analgesia through a thoracic epi-
dural catheter positioned with its tip at the T4 level. This
eliminated the need for intraoperative systemic narcotics and pro-
vided optimal postoperative pain management with minimal respi-
ratory depressants.
On the first postoperative day, use of a bedside treadmill
supplemented the efforts of experienced physiotherapists and tho-
racic surgical nurses to provide vigorous chest physiotherapy and
ambulation. Despite this intensive program, minitracheostomy
(Cook Cricothyrotomy Catheter, Cook Inc., Bloomington, Ind) for
tracheal suction was frequently used for patients with thick secre-
tions and feeble coughs.
TABLE 1. Guidelines for evaluating patients for LVRS
Inclusion criteria Exclusion criteria
General
Disability despite maximal rehabilitation Inability to participate in rehabilitation
Cessation of tobacco use 6 mo Continued use of tobacco
Patient expectation of goals reasonable Significant comorbidity
Previous pleurodesis or thoracotomy
Underweight, overweight
Anatomic radiographic evaluation
Marked emphysema Bronchiectasis
Minimal radiographically evident emphysema
Heterogeneously distributed emphysema
Target zones of poorly perfused lung
Areas with better preserved lung
Homogeneously distributed emphysema
No target zones
No preserved lung tissue
Marked thoracic hyperinflation Chest wall or thoracic cage abnormalities
Physiologic evaluation
Marked airflow obstruction Minimal to moderate airflow obstruction
Marked hyperinflation Minimal to moderate thoracic hyperinflation
Alveolar gas exchange
DLCO 50%
Cardiovascular function
Essentially normal ejection fraction
Markedly disordered alveolar gas exchange
DLCO 10%
PaCO2 60 mm Hg
Cardiovascular dysfunction
Left ventricular ejection fraction
40%
Mean pulmonary artery pressure
35 mm Hg
Significant coronary artery disease
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Statistical Analysis
Descriptive statistics are expressed as mean  SD unless other-
wise specified. Categoric data are expressed as counts and propor-
tions. Comparisons were done with paired, two-tailed t tests for
means of normally distributed continuous variables and Wilcoxon
rank sum tests for skewed data. Either 2 or Fisher exact tests were
used to analyze differences among the categorical data. Kaplan-
Meier estimation was used to depict survival.
Cox multivariate proportional hazards regression was used to
identify risk factors for death after LVRS. The time to death was
selected as the principal outcome. The regression models were
constructed with dependent variables known or suspected to be
independent predictors of survival on the basis of previous pub-
lished results and the univariate differences observed between our
subgroups. The following categoric variables were considered:
gender, distribution of disease (upper vs lower lobe predomi-
nance), patients with both a preoperative FEV1 and DLCO percent
predicted of 20% or less compared with the remaining patients,
and preoperative PaCO2 measurement stratified as 50 mm Hg or
less versus more than 50 mm Hg. The following continuous
variables were considered: age in years, preoperative FEV1 in
liters, RV in liters, DLCO in milliliters per minute per millimeter of
mercury, and 6-minute walk test in feet. All data analysis was
performed with Systat (Systat 10.0 for Windows; SPSS Inc, Chi-
cago, Ill).
Results
Baseline
The mean age was 62  8 years. All patients were former
smokers, and 50% were female. As expected, most patients
(n  229) were seen with the major focus of disease in the
upper lobes; however, the most severe destruction was in
the lower lobes in 21 patients (8.4%), including 12 patients
(4.8%) with known 1-antitrypsin deficiency. Preoperative
pulmonary function, 6-minute walk data, arterial blood gas
values, and oxygen supplementation requirements of all
patients who underwent bilateral LVRS are depicted in
Tables 2 and 3.
Hospital Course
The 90-day and complete in-hospital mortalities in this
series were 4% (n  10) and 4.8% (n  12), respectively.
All early postoperative deaths were attributed to respiratory
failure, except 1 that was attributed to pulmonary embolism
(Table 4). There were no intraoperative deaths.
Prolonged air leaks (7 days) were the most common
complication (45.2%, n  113). Reexploration rates for air
leak and bleeding were 3.2% (n  8) and 1.2% (n  3),
respectively, and reexplorations occurred more frequently
early in the series. Eighteen patients (7.2%) required rein-
tubation at some time during the hospital stay. Ten of these
patients progressed to require a tracheostomy, and 8 were
extubated. All patients were weaned from mechanical ven-
tilation before discharge. Other operative morbidities are
listed in Table 4. The median length of hospitalization in the
survivors was 9 days (range 4-168 days). A minitracheos-
tomy was placed in 43 patients (17.2%), either in the oper-
ating room or later at the bedside.
Follow-up Information
Follow-up ranged from 1.8 years to 9.1 years (median 4.4
years). Only 1 patient was unavailable for follow-up. Nine-
ty-six (38.4%) of 250 patients have died, most (65.6%) of
respiratory failure.
The Kaplan-Meier estimate of survival at 5 years after
LVRS was 67.7% (n 108), as shown in Figure 1. Eighteen
patients (7.2%) have subsequently undergone lung trans-
plantation after a median interval of 4.3 years (range 2.1-
6.4). All 18 of these patients survived the initial posttrans-
plantation hospitalization.
TABLE 2. Pulmonary function and exercise test results before and after surgery
Evaluation baseline
(n  249)
After rehabilitation
(n  249)
6 mo PO
(n  231)
1 y PO
(n  225)
3 y PO
(n  178)
5 y PO
(n  106)
Time from surgery (d, mean  SD) 124 79 6 5 193 36 401 60 1076 133 1799 217
FEV1
Mean  SD (L) 0.7 0.2 0.7 0.3 1.1 0.5 1.0 0.5 0.9 0.5 0.8 0.5
% predicted 25%* 26% 39%† 38%† 34%† 30%‡
RV
Mean  SD (L) 5.9 1.4 5.8 1.3 4.0 1.2 4.1 1.3 4.2 1.3 4.8 1.8
% predicted 282%* 277% 189%† 193%† 198%† 222%†
RV/total lung capacity (%, mean  SD) 72 7* 70 7 57 9† 58 10† 61 11† 66 11†
DLCO
Mean  SD (mL/[min  mm Hg]) 9.1 3.7 8.9 3.9 10.4 4.6 10.3 4.3 9.2 4.1 8.6 4.2
% predicted 34%* 33% 39%† 39%† 36%* 34%*
6-min walk (mean  SD, ft) 919 335† 1142 291 1345 316† 1341 310† 1271 305† 1154 348*
PO, Postoperative.
*P  .05 for paired analyses with scores after rehabilitation.
†P  .001 for paired analyses with scores after rehabilitation.
‡P .02 for paired analyses with scores after rehabilitation.
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Functional Results
Pulmonary function test results are shown in Table 2. More
than 95% of evaluable patients had objective pulmonary
function information available at each follow-up period.
Spirometric parameters, lung volumes, and gas exchange
improved after surgery. The FEV1 and RV showed statisti-
cally significant improvements between preoperative values
and each time point of follow-up. There were no statistically
significant differences between initial evaluation and pos-
trehabilitation FEV1 and RV. Six months after the opera-
tion, FEV1 had increased in 94% of patients; the mean
change from preoperative values was 54%. After 5 years,
the mean change in FEV1 was an improvement of 7%, and
53% of patients still had an increase relative to the preop-
erative value. Six months and 1 year after the operation, RV
had declined by 30%, and 90% of patients showed improve-
ment. At 5-year follow-up, 79% of patients still showed an
improvement, and the mean RV showed a decrease of 14%
from the preoperative value.
The DLCO data showed a 25% increase from preoperative
values on follow-up at 6 months and 1 year. At those time
points, 67% of patients had improvement with respect to
baseline. At 3 and 5 years, the difference did not reach
statistical significance, but at 5-year follow-up there was
still an average of 7% of increase from preoperative value,
with 53% of patients showing improvement.
Results from gas exchange and oxygen supplementation
requirements are shown in Table 3. The mean PaO2 had
increased by 8 mm Hg at 6-month, 1-year, and 3-year
follow-ups and by 5 mm Hg at 5 years. Seventy-nine
percent of patients showed improvement at 3 years, and
66% still did so at 5-year follow-up.
Supplemental oxygen requirements at rest substantially
declined after the operation (45% vs 12%, 15%, and 22% at
1, 3, and 5 years, respectively). Before the operation, 92%
of patients required supplemental oxygen with maximum
exertion. At 6 months, 1 year, and 5 years, the percentages
were 50%, 56%, and 80%, respectively.
Functional improvement was also measured by the
6-minute walk test, and results are shown in Table 2. There
was a significant improvement in physical ability during the
preoperative rehabilitation period. There was a further in-
crease in performance after the operation. This improve-
ment was maintained for 3 years, followed by a gradual
decline. Exercise tolerance scores after 5 years were not
worse than preoperative scores.
The Medical Research Council Dyspnea Scale showed a
reduction of dyspnea at 6 months, when 88% of patients
reported improvement (Figure 2). These improvements
were sustained through the 1-year follow-up period, when
79% of patients were still showing improvement, 18% had
no change, and only 3% showed worsening. At 5 years after
the procedure, only 20% of patients reported a worse score.
Health-related quality of life, according to the SF-36
Physical Functioning (PF) Scale scores, showed marked
TABLE 3. Alveolar gas exchange and oxygen supplementation before and after surgery
Evaluation
baseline
(n  249)
After
rehabilitation
(n  249)
6 mo PO
(n  231)
1 y PO
(n  225)
3 y PO
(n  178)
5 y PO
(n  106)
PaCO2 (mm Hg) 42 6 42 6 39 5 39 5 42 6 42 6
PaO2 (mm Hg) 64 9 64 9 72 10 72 11 72 13 69 11
Supplemental oxygen
Required continuously
(% of patients)
60.8% 44.8% 11.3% 12.4% 15.2% 22.6%
Required during exercise
(% of patients)
83.6% 91.6% 50.2% 56.4% 70.1% 80.0%
PO, Postoperative.
TABLE 4. Hospital course data for first 250 consecutive
patients undergoing LVRS
Event
Frequency (n  250)
No. %
Morbidity 138 55.2
Prolonged air leak (7 d) 113 45.2
Pneumonia 24 9.6
Reintubation 18 7.2
Tracheostomy 10 4
Small bowel obstruction or ileus 6 2.4
Myocardial infarction 5 2.0
Deep vein thrombosis 4 1.6
Cecal perforation 2 0.8
Phrenic nerve injury 2 0.8
Subsequent operation 18 7.2
Reexploration
Prolonged air leak 8 3.2
Bleeding 3 1.2
Gastrointestinal complication 6 2.4
Coronary artery bypass grafting 1 0.4
In-hospital mortality 12 4.8
Hospital stay of survivors (d)
Median 9
Range 4-168
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improvement relative to that reported by the same patients
after rehabilitation but before the procedure (Figure 3). At 6
months, 1 year, 3 years, and 5 years after the operation, 97%
96%, 93%, and 92% of the evaluable patients, respectively,
responded to the SF-36 PF questionnaire. The SF-36 PF
questionnaire is scored on a scale of 100, with 0 being the
worst and 100 being the best. Before the operation, the
mean baseline score was 18, indicating very severe limita-
tion. The score peaked at 58 points at 6 months, and after 5
years almost 80% of patients still reported improvement
relative to their own baseline scores. One subsection of the
SF-36 PF Scale asks the patient to compare his or her health
with that 1 year earlier. Ninety-six percent of patients felt
better at 6 months after the operation, and almost 88% did
so at 1 year.
When asked to assess their own satisfaction with the
operation, 97% of patients reported good or excellent over-
all satisfaction 6 months after the procedure. At 5 years,
only 18% reported poor or fair satisfaction (Figure 4).
Longitudinal data with a shrinking cohort of observable
patients are prone to bias. To try to dissect out the role of
dropouts as a result of death, we separately analyzed data
from the cohort of patients with complete data at all time
points out to 5 years (Table 5). These data were comparable
to the data from the overall data pool (Table 2). Both
demonstrated that on average half of the initial improve-
ment in FEV1 was lost at 3 years, with a return to the
baseline value at 5 years. Thus there is no evidence that the
mean values obtained late in follow-up were inappropriately
elevated by the dropping out of the lower values. For the
Figure 1. Kaplan-Meier survival graph after LVRS. Data were censored for missing data (1 patient), lung
transplantation (18 patients), or end of follow-up.
Figure 2. Respondent score changes in Modified Medical Research Council Dyspnea Scale after LVRS.
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5-year cohort, the health-related quality of life scores ac-
cording to the SF-36 PF analysis at each time point were
essentially the same as in the overall analysis of the fol-
low-up data for all patients.
To better assess our selection criteria, we separately
analyzed results achieved in patients for whom LVRS has
been especially controversial. This group included patients
with lower lobe destruction and those with the most se-
verely impaired lung function, specifically those with both
FEV1 and DLCO values 20% or less of predicted values.
Twenty-one patients in this cohort had predominantly
lower lobe destruction and underwent bilateral lower lobe
LVRS. Of these, 12 had 1-antitrypsin deficiency. Results
of the lower lobe group are compared with the upper lobe
resection group in Table 6. The 6-month results of the two
groups were similar, but thereafter the loss of function in the
lower lobe group appeared to occur at a much higher rate
than that seen in the upper lobe group. The mean FEV1 at 5
years in the lower lobe group was below the baseline value,
whereas the mean FEV1 in the upper lobe group remained
9% above the baseline value. A similar accelerated rate of
decline for the lower lobe group was observed in the
6-minute walk distance.
Patients with both a low FEV1 and a low DLCO (20% of
predicted) have recently been identified by the NETT study
as being at high risk in undergoing LVRS. The NETT
interim report suggests excessive early mortality and poor
functional outcome.13 Twenty such patients (8%) were iden-
tified in this series, and the results in this group are shown
in Table 7. The initial improvements in both FEV1 percent-
age and 6-minute walk test for the high-risk group exceeded
those for all other patients. Furthermore, the high-risk group of
patients showed a larger improvement in DLCO at 6 months
than did all other patients (70% vs 21% improvement).
Figure 3. SF-36 PF Scale scores from before LVRS (baseline) and after surgery.
Figure 4. Postoperative patient overall satisfaction.
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A Cox proportional hazards model assessing for prog-
nostic factors for death was performed (Table 8). This
analysis identified advanced age, male gender, low FEV1,
and reduced 6-minute walk distance as statistically signifi-
cant risk factors for death. A higher risk was also found in
patients with a PaCO2 greater than 50 mm Hg and in those
with predominantly lower lobe disease. The risk factor for
mortality for patients with both a preoperative FEV1 and a
preoperative DLCO no greater than 20% of predicted ap-
proached but did not reach statistical significance.
Discussion
LVRS is a palliative treatment for the symptoms of emphy-
sema, designed to relieve dyspnea and improve the ability to
participate in the routine activities of daily living without
significant limitation. The operation is to be considered after
maximal medical therapy has failed to produce satisfactory
palliation. The operation is not intended to retard the natu-
rally progressive course of the underlying disease, but rather
is meant to return the emphysematous lung and hyperin-
flated thorax to an earlier stage in the natural history of
obstructive lung disease. Many large longitudinal stud-
ies23-26 of patients with severe chronic obstructive pulmo-
nary disease have demonstrated increased mortality relative
to the general population. When the FEV1 is less than 30%
of predicted, 50% of patients will die within 3 to 4 years.
Two of the major unresolved issues in LVRS are how to
select appropriate candidates and how to assess and inter-
TABLE 5. Change in function with time for a cohort of patients with complete data
After rehabilitation 6 mo PO 1 y PO 3 y PO 5 y PO
FEV1 (n  95)
Mean  SD (L) 0.75 0.1 1.17 0.1 1.08 0.2 0.92 0.3 0.81 0.1
% predicted 26% 41% 38% 33% 30%
RV (n  75)
Mean  SD (L) 5.8 1.0 3.9 0.8 4.2 0.9 4.2 0.9 4.8 1.0
% predicted 276% 183% 195% 194%) 210%)
DLCO (n  70)
Mean  SD (mL/ [min  mm Hg]) 9.4 3.5 11.4 4.1 11.5 4.3 10.0 4.1 9.2 4.0
% predicted 33% 42% 43% 38% 33%
6-min walk (ft, mean  SD, n  93) 1177 243 1470 375 1408 278 1309 317 1159 316
SF-36 PF Score (mean  SD, n  88) 18 6 66 16 61 12 46 16 33 13
Numbers of patients are those with selected outcome variables that were measured at every time point. PO, Postoperative.
TABLE 6. Subgroup analysis of pulmonary function and exercise test results before and after surgery between patients with
predominately lower lobe distribution of disease and those with predominately upper-lobe distribution
After rehabilitation 6 mo PO 1 y PO 3 y PO 5 y PO
Lower lobe (n  21)
FEV1
Mean  SD (L) 0.65 0.2 1.01 0.6 0.75 0.3 0.72 0.3 0.59 0.2
% predicted 22% 30% 27% 26% 21%
% change* NA 54 69 18 31 14 49 14 23
6-min walk
Mean  SD (ft) 1210 230 1450 405 1315 379 1338 295 1240 361
% change* NA 19 32 9 28 9 28 7 28
Kaplan-Meier survival NA 100% 95.2% 79.8% 59.9%†
Upper lobe (n  229)
FEV1 0.72 0.3 1.10 0.5 1.07 0.5 0.92 0.5 0.84 0.5
Mean  SD (L)
% predicted 26% 40% 39% 34% 31%
% change* NA 54 42 49 48 26 41 9 32
6-min walk
Mean  SD (ft) 1135 295 1336 305 1344 304 1264 306 1145 348
% change NA 23 39 22 35 17 44 14 40
Kaplan-Meier survival NA 94.3% 93.0% 84.3% 68.6%†
PO, Postoperative; NA, not applicable.
*Mean percentage change of postoperative value from preoperative (after rehabilitation) value.
†P  .53 for Mantel-Haenszel log-rank test comparing Kaplan-Meier survival.
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pret the results. Despite considerable experience, our selec-
tion process admittedly contains a significant subjective
component, and at our institution we continue to be conser-
vative in our selection criteria. The indications for LVRS
have remained essentially unchanged, and we strongly be-
lieve that patient selection in terms of both potential benefit
and potential risk is key to the success of this procedure. We
also strongly believe that rigorous preoperative preparation,
including exercise rehabilitation, best prepares these high-
risk patients for operation. The morbidity and mortality
reported in this group of 250 patients was comparable to
that seen in the group of 150 reported on previously. These
findings give support to the assertion that we have been
consistent and stable in selection and treatment.
The results of the PFTs were characterized by an increase
in spirometric parameters and a decrease in lung volumes.
Pulmonary rehabilitation increased stamina and exercise
tolerance, but it has not been found to produce a change in
the FEV1 or RV between baseline and postrehabilitation
values.2 The improvement after surgery was statistically
significant at each follow-up time point, and FEV1 and RV
were preserved through 5 years in 53% and 80% of patients,
respectively. Because medical therapy had been optimized
before the preoperative PFTs, the postoperative improve-
ments in the spirometric parameters must be attributed to
the beneficial effects of the surgery and not to the ongoing
medical management. The correlation between FEV1 and
life expectancy is well known.23-26 Therefore the improve-
ment in FEV1 found in all LVRS series may have a sub-
stantial impact on patients’ longevity, as we demonstrated
in a previous report of 87 Medicare patients accepted for
LVRS in 1995, 22 of whom were denied the operation
because of the subsequent withdrawal of Medicare funding
for the procedure.27 At 2 years, objective and subjective
measurements of pulmonary function were improved in the
surgical group but had worsened in those denied surgery.
This report confirmed the natural history of the disease in
the patients considered suitable for LVRS, who showed a
progressive decline, in contrast to the findings of improved
physiologic function seen in patients after the LVRS pro-
cedure. Follow-up of these patients to the present reveals a
median survival of 3.4 years for those denied the operation
versus 5.9 years for those who underwent LVRS.
With regard to the perioperative course, this report ech-
oes previous reports by our group and others that carefully
selected patients face a 5% risk of postoperative death. This
TABLE 7. Subgroup analysis comparing pulmonary function and exercise test results before and after surgery between
patients with both a preoperative FEV1 and DLCO percent predicted < 20% after rehabilitation and all other patients
After rehabilitation 6 mo PO 1 y PO 3 y PO 5 y PO
Both FEV1 and DLCO  20% (n  20)
FEV1
Mean  SD (L) 0.46 0.1 0.78 0.3 0.81 0.3 0.74 0.3 0.66 0.2
% predicted 17% 32% 31% 25% 24%
% change* NA 73 63 82 72 47 91 36 52
DLCO
Mean  SD (mL/ [min  mm Hg]) 4.2 0.9 7.0 3.1 7.2 3.2 6.9 3.4 6.2 2.3
% predicted 16% 27% 28% 26% 25%
% change* NA 70 53 78 62 67 58 51 42
6-min walk
Mean  SD (ft) 913 235 1158 289 1179 294 1124 322 1100 204
% change NA 27 41 28 39 26 42 25 24
Kaplan-Meier survival NA 95.0% 95.0% 84.4% 59.1%†
All others (n  230)
FEV1
Mean  SD (L) 0.74 0.3 1.12 0.5 1.06 0.5 0.93 0.5 0.82 0.5
% predicted 26% 41% 38% 33% 30%
% change* NA 52 42 43 44 23 38 6 30
DLCO
Mean  SD (mL/ [min  mm Hg]) 9.3 3.8 10.7 4.6 10.5 4.2 9.4 4.1 8.7 4.3
% predicted 34% 41% 40% 37% 34%
% change* NA 21 46 16 41 2 31 8 28
6-min walk
Mean  SD (ft) 1161 287 1360 313 1355 308 1284 301 1158 356
% change NA 23 38 21 35 15 43 2 40
Kaplan-Meier survival NA 94.8% 93.5% 83.9% 68.9%†
PO, Postoperative; NA, Not applicable.
*Mean percentage change of postoperative value from preoperative (after rehabilitation) value.
†P  .28 for Mantel-Haenszel log-rank test comparing Kaplan-Meier survival.
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report presents additional long-term follow-up to the mid-
term results reported in our last case series report.5 The
main additions provided by this report are the addition of
100 patients, to add weight to the perioperative statistics of
morbidity and mortality, and the addition of substantial
follow-up to better describe the natural history of emphy-
sema after bilateral LVRS.
We have consistently stressed the importance of a het-
erogeneous anatomic distribution of emphysema and made
the observation that a low DLCO (20%) was associated
with increased mortality, representing a relative contraindi-
cation. The NETT trial recently reported that two groups of
patients were found to have high risks for postoperative
death and poor functional outcome after LVRS. These two
groups were those with a pattern of severe homogeneous
emphysematous destruction (homogeneous distribution,
FEV1 20% of predicted) and those with severe functional
impairment (FEV1 and DLCO both 20% of the predicted
value). These findings corroborate observations from the
early LVRS experience, and the statistically sound nature of
a prospectively randomized trial has added additional
weight of evidence to the belief that such patients are poor
candidates. Because we have excluded patients with a ho-
mogeneous pattern of emphysematous destruction, our se-
ries does not address the issue of whether homogeneous
destruction is an absolute or relative contraindication. Oth-
ers have suggested that highly selected patients with a
homogeneous pattern but only moderate functional impair-
ment may receive significant benefit from LVRS.28 Presum-
ably the long awaited results of the NETT trial will shed
additional light on this matter.
We also agree that patients with severe functional im-
pairment, as reflected by both FEV1 and DLCO no greater
than 20% of predicted value, have a very high risk. Our
series included 20 such patients. Paradoxically, this group
of patients achieved a percentage improvement greater than
that seen in the rest of the series. The marked improvement
in FEV1 might be expected in this highly selected group of
patients with major target areas and low FEV1. A similar
increment in FEV1 would produce a greater percentage
change than observed in patients with higher initial FEV1. A
low DLCO may result either from extensive loss of diffusing
surface as a result of emphysematous destruction or from
marked hypoventilation of potentially functional pulmonary
parenchyma. Such hypoventilation may occur in candidates
for LVRS with a heterogeneous pattern of destruction when
the marked overinflation of the target areas significantly
compromises ventilation to portions of the remaining lung.
In this situation, excision of the destroyed areas restores
ventilation to better-preserved areas, with a resulting im-
provement in postoperative DLCO. These patients were se-
lected on the basis of the presumption that the low DLCO was
the result of underventilation of preserved lung. The func-
tional improvement after resection of target areas is mir-
rored by the improved DLCO.
In this series, the major focus of disease was located in
the lower lobes in 21 patients, 12 of whom had 1-antitryp-
sin deficiency. These patients have shown significant func-
tional improvement at 6 months after surgery but a decline
of benefit at 1 year (Table 6). The explanation for this lack
of benefit is not certain. In our early experience, lower lobe
resections were smaller than the more extensive resection
currently performed. We know from postoperative radio-
graphs and our experience with several of these patients
TABLE 8. Results of multivariate analysis of prognostic factors influencing survival for patients after bilateral LVRS
Variable N
Relative
risk
95% Confidence
interval
P
value
Age (y) 250 1.038 1.005-1.073 .026
Gender
Male 124 Reference — —
Female 126 0.543 0.334-0.884 .014
Disease predominance
Upper lobe 229 Reference — —
Lower lobe 21 1.554 0.742-3.254 .242
FEV1 (L)* 250 0.213 0.067-0.671 .008
RV (L)* 250 1.013 0.834-1.232 .892
DLCO (mL/ [min  mm Hg])* 250 0.942 0.868-1.022 .154
6-min walk (ft)* 250 0.996 0.994-0.999 .003
FEV1 and DLCO†
All others 230 Reference — —
20% 20 1.508 0.803-2.835 .094
PaCO2 (mm Hg)*
50 217 Reference — —
50 33 1.121 0.872-1.631 .126
*Preoperative pulmonary function and gas exchange measurements.
†Both preoperative FEV1 and DLCO percent predicted measurements up to 20%.
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who subsequently underwent transplantation that the dia-
phragm was tethered to the chest wall and relatively immo-
bile. Finally, it is possible that these patients had more
extensive emphysema than was present in the group with
upper lobe predominance. Kaplan-Meier estimation of sur-
vival did not show a statistically significant difference be-
tween the two groups, although the hazard function in the
Cox model suggests that this may have been a sample size
issue. Because of this early loss of benefit in lower lobe
LVRS recipients, we recommend that only highly selected
patients with predominantly lower lobe distribution of dis-
ease be considered. This would include patients whose
upper lobes show only mild to moderate emphysema on
computed tomographic scan and in whom the DLCO is
greater than 20% predicted.
Follow-up was essentially complete, avoiding the inevi-
table bias produced by selective follow-up results. Work by
Butler and associates29 suggests that patients lacking fol-
low-up data are the most likely to have a poor result.
Previous criticism of the reporting of data from an ever-
shrinking cohort of patients followed with time led us to
analyze the data from the cohort of patients with complete
5-year follow-up (Table 5). The increase in FEV1 and
decrease in RV occurred primarily during the first year after
surgery and, despite the inevitable progression of emphy-
sema, appeared to last at least 5 years. When we looked at
the patients who completed the 5-year follow-up with all the
measurements at each time point, results therefore did not
differ from the results obtained by analyzing all available
patients. In this cohort of patients who completed 5-year
follow-up, we assessed the rate of decline of half of the
benefit. In terms of FEV1, half of the benefit was lost by 3
years. The most persistent benefit seemed to be in RV,
which appeared to be temporally related to sustained reduc-
tion in dyspnea and improvement in exercise tolerance. This
is not unexpected, because the reduction in residual volume
is probably the factor most responsible for the reduced work
of breathing, lessened dyspnea, and improved exercise tol-
erance seen after LVRS. These are all directly a result of
thoracic hyperinflation, and a reduction in RV most accu-
rately reflects this reduction. The FEV1 is a measurement
that is easily obtained, highly reproducible, and highly
correlated with longevity in patients with severe emphy-
sema.
This report documents a prospective controlled consec-
utive case series with data acquisition throughout our entire
experience with bilateral LVRS. Each patient served as his
or her own control, after maximum medical management
had been optimized and no further benefit could be
achieved. Under these circumstances LVRS was used not as
an alternative therapy but as the only potentially efficacious
therapy other than, for some, lung transplantation. The
natural history of end-stage emphysema is well known and
is documented for patients with end-stage emphysema in
general. Furthermore, in six randomized trials comparing
LVRS with best medical therapy, LVRS candidates ran-
domly assigned to the medical control arm showed progres-
sive declines in lung function and exercise tolerance. The
magnitude of improvement in both objective and subjective
outcome measures produced by LVRS was significant, not
only statistically but also in terms of impact on the patient’s
quality of life. Furthermore, the vast majority of patients
received a substantial beneficial effect. For all of these
reasons—the well documented natural history of progres-
sive decline, the absence of an alternative therapy, the
magnitude of the functional improvement, and the fre-
quency of beneficial effects—we chose a prospective con-
trolled consecutive case series rather than a randomized
clinical trial to assess the benefit of LVRS. We acknowl-
edge, however, that only a randomized clinical trial can
provide a true estimate of the “value” of the procedure by
comparing the benefit achieved with the operation with the
progressive decline exhibited by an identical control group.
Furthermore, only a long-term randomized clinical trial in
which half of the patients are denied access to the operation
can accurately define the effect of LVRS on longevity.
Conclusion
Our experience leads us to conclude that careful patient
selection, rigorous preoperative preparation, and detailed
operative and perioperative care are all necessary for suc-
cessful LVRS. The operation appears to provide improved
pulmonary function and quality of life, increased exercise
tolerance, and decreased requirement for supplemental ox-
ygen. The most recent follow-up data confirm persistent
objective benefits at 5 years for most patients.
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Discussion
Dr Larry R. Kaiser (Philadelphia, Pa). Let me state at the
outset that the only conflict I have is that I have been a tremendous
admirer of Dr Cooper ever since I was his resident about 18 years
ago, if that counts as a conflict. I appreciate the opportunity to
discuss this important article. My congratulations to Dr Ciccone,
the current Graham Memorial Traveling Fellow, for an outstanding
presentation.This is an important article for a number of reasons. It
is the first report detailing long-term follow-up for patients under-
going LVRS. With a median follow-up of 4.4 years, we now know
the natural history of the disease progression after the surgical
procedure. Remarkably, only 1 patient was unavailable for follow-
up. The study was carried out as a prospective controlled consec-
utive case series, with data collected from the beginning of the
experience. Ciccone and colleagues have demonstrated that, with
careful patient selection, the operation can be accomplished with
less than 5% perioperative mortality, with most patients showing a
significant improvement in quality of life, and they have shown
how long this improvement lasts. They have delineated the selec-
tion factors that define the optimal patient for this operation and
have convincingly demonstrated that for these selected patients
LVRS is a superior alternative to the best medical therapy.
Should we discount the results presented today because the
study design was not experimental; that is, it did not involve
random assignment of treatment? I would argue, and this view is
supported by others who have looked at the question in consider-
ably greater detail than I, that a carefully designed observational
study such as this can provide results equivalent to those that can
be obtained by a randomized trial. Short of demonstrating a sur-
vival advantage for the procedure, a claim never made by those
doing the operation, a randomized trial would add little. Six
randomized trials have already demonstrated a significant treat-
ment advantage in the group undergoing operation. This study
extends the information from the randomized trials in that it
answers questions regarding long-term results.
I have several questions, Dr Ciccone. First, in the article you
discussed a change in the operative technique from an oblique line
of parenchymal resection to a transverse one, removing almost the
entire upper lobe. What led to this change, and do you think that
this influenced the outcomes of the more recent patients? Have you
been able to define guidelines regarding how much lung to resect?
Patients with basilar disease had an early improvement in function
similar to that in those with apical disease but showed a rapid
decline. Would you still operate on patients with basilar disease?
Finally, 9 patients had non–small cell lung cancer found in the
resected specimen, and in 4 of these the finding was purely
incidental. Have any of these 9 patients died of lung cancer? Did
any patient have an incomplete resection that, under ideal circum-
stances, would have prompted a reoperation?
I end by noting that the information needed by the Centers for
Medicare and Medicaid Services for a coverage decision has just
been presented. I can only hope that the powers that be at the
Centers for Medicare and Medicaid Services get the message so
that selected Medicare patients with emphysema can benefit from
this procedure.
To repeat, my first question concerned the change in the tech-
nique from the oblique resection to the transverse resection. Did
that make any difference in the results in the later patients?
Dr Ciccone. Regarding the shift to a transverse resection, we
do not think that this has made a lot of difference. I have several
times heard Dr Cooper say the day after surgery that he wished he
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had cut out less lung, because of a pleural space problem. Six
months after surgery, however, he wished he had cut out more
parenchyma, because the good results probably would have been
even better.
Dr Kaiser. Do you have any guidelines as to how much to
resect?
Dr Ciccone. No, there are no precise guidelines. The technique
changed from an inverted U-shape that goes from the anterior
aspect of the upper lobe toward the apex and then down the back.
The current technique is just a resection from the front, straight
toward the back, removing almost all of the upper lobe on the
right. On the left, the portion of the upper lobe is removed almost
completely, and just the lingula is left intact.
Dr Kaiser. My third question concerned those patients with
basilar disease—lower lobe disease. They showed an early im-
provement that did not seem to last. Do you still operate on such
patients?
Dr Ciccone. We still operate on these patients. We had 21 of
these patients in this series, and 12 of these had a deficiency of the
enzyme 1-antitrypsin. We just recommend that surgeons be
highly selective with such patients. Although they showed good
results at 6 months, exactly the same as the other patients with the
upper lobe predominance of disease, they appeared to lose the
benefit of this operation more rapidly.
Dr Kaiser. Nine patients had lung cancers. Have any of those
patients died of their malignancies? And in 4 cases the disease was
found by the pathologist and not noted at the time of operation.
Were any of those incomplete resections?
Dr Ciccone. Of these 9 patients, 5 were known to have ma-
lignancy before the operation. In the other 4 cases, it was found at
surgery. As for late death after LVRS, 84 of these patients died,
and 4 of the 9 patients with carcinoma died late after the operation,
2 of the 4 of recurrent carcinoma and the remaining 2 of respira-
tory failure. I do not have available other specific details on the
deaths of the 9 patients with cancer in the resected specimen.
Dr Thomas W. Rice (Cleveland, Ohio). I compliment this
group for leading the charge in showing that we can get good
results with careful follow-up of our patients. Dr Ciccone, can you
tell us how you are going to apply this information to your patients
in Rome? How will you use this study to help you select patients
in Rome for LVRS?
Dr Ciccone. We already do this kind of operation in Rome.
Our group of patients is not so consistent, and we alternate on a
case-by-case basis between median sternotomy, which is our first
choice, and thoracoscopy, which we use for severely compromised
patients. In Rome, as in this series, the unilateral procedure is
given to selected patients, typically patients with contraindications
to bilateral LVRS.
Dr Rice. Can you tell us any operative hints that Dr Cooper has
taught you?
Dr Ciccone. Well, I don’t know whether I am allowed to say
that. Probably Dr Cooper should answer this question.
Dr Joseph E. Bavaria (Philadelphia, Pa). I just wanted to ask
you two questions. First, what was the percentage of patients who
ended up with single-lung transplants?
Dr Ciccone. I don’t remember the exact percentage, but there
were 18 patients who underwent transplantation after LVRS.
Dr Bavaria. Second, what was their mean age?
Dr Ciccone. The mean age of the patients undergoing LVRS
was 62 years.
Dr Bavaria. And those undergoing transplantation?
Dr Ciccone: The mean age of patients who underwent LVRS
and went on to lung transplantation was 54 years.
Dr Cooper (St Louis, Mo). Thank you for the opportunity, and
thank you, Anna Maria, for a wonderful presentation. I have a lot
of people to thank, my colleagues and the people at our institution,
who in spite of the political maelstrom associated with this oper-
ation have been extremely supportive, and I am grateful to them.
This operation has become a lightning rod, because it occurred
in a day when evidence-based medicine is being used as the
watchword as to how new procedures should be introduced. I think
that we have all learned something. There is no question that after
the initial presentation at this meeting in, I believe, 1994, a lot of
people began doing some sort of LVRS, often with poor selection
and inadequate resources, and this led to a lot of problems. I think
it behooves us all to look carefully at how we can introduce new
procedures and new technologies in a responsible fashion and
avoid hype, avoid exaggerated claims, and do it in an objective
manner. It is important for our patients, for payers, and for society
to ensure that new procedures are introduced in a careful and
cautious yet timely fashion. I am not sure that we have a mecha-
nism yet in this country for such a process, but I think that
organizations such as this can play a major role.
I don’t know any tricks yet. This is not a technically difficult
operation. It is deceptively simple, and perhaps therein lies the
danger. The trick is really in the selection and the postoperative
care of the patients, and my colleagues and our staff have a lot
more to do with that than I do.
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